Veritas In Silico Inc. [130A.T]
TOKYO, May 11 (Pulse News Wire) – Veritas In Silico Inc. (130A.T) and SpiroChem AG have finalized a joint exploration research agreement aimed at developing advanced mRNA-targeted small molecule drugs.
The collaboration leverages SpiroChem's expertise in macrocycles, peptides, and peptidomimetics, combined with Veritas In Silico’s AI-driven mRNA drug discovery platform, aibVIS, and cellular experimentation techniques. Under the agreement, the companies plan to investigate novel macrocycles, peptides, and peptidomimetics that interact with promising mRNA motifs identified through initial screening efforts conducted at Veritas In Silico. They also intend to explore compounds exceeding the Rule of 5 criteria, aiming to deepen understanding of structure-activity relationships in RNA recognition and establish design principles for future drug development.
Both firms expect to monetize their findings through partnerships, licensing deals, or joint ventures with biotech and pharmaceutical companies. Veritas In Silico President Shin-go Nakamura highlighted the potential synergy between SpiroChem’s compound library and his company’s AI-powered mRNA drug discovery platform, which could lead to breakthroughs in RNA-targeted therapeutics. No upfront payments are anticipated under the contract, and expenses related to the joint research are included in Veritas In Silico’s fiscal 2026 budget.
The company does not foresee significant impacts on its performance metrics due to this collaboration.
🟢 Confidence: High AI-translated content.